Sign up to save your podcasts
Or
Share Glaukos Submits NDA for Epi-On CLX Candidate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Glaukos Submits NDA for Epi-On CLX Candidate
Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Eyewire NewsGlaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders.
Learn more about your ad choices. Visit megaphone.fm/adchoices